← SynDRA
LXR-623
SynDRA canonical compound SYN0018791 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ABCA1 | AR | NR1H2 | NR1H3 | NR1I2 | NR3C1 |
|---|
| Mechanism of action | LXR agonist |
|---|
All known targets
- NR1H2
- NR1H3
- ABCA1
- AR
- NR1I2
- NR3C1
Mechanisms of action (all sources)
- NR1H2 AGONIST
- LXR-beta agonist
- NR1H3 AGONIST
- LXR-alpha agonist
- LXR agonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- RXRA
- ABL1
- PPARA
- NR3C2
- NR4A1
- NR5A1
- NTHL1
- OGG1
- PGR
- PPARD
- AURKA
- PPARG
- SMUG1
- TDG
- THRA
- THRB
- TRIM24
- NR2E1
- NR2C1
- NR1H4
- FGFR3
- BRD4
- BRPF1
- CDK2
- CSNK1D
- ESR1
- ESR2
- GSK3B
- NEIL2
- HDAC6
- HNF4A
- MAPK1
- MBD4
- MUTYH
- NEIL1
- UNG
Cross-references
Synonyms
- LXR 623
- LX-623
- LX623
- WAY252623
- LXR-623 (WAY 252623)
- LXR623
- WAY-252623
- RefChem:925016
- WAY 252623
- MFCD16495812
- C21H12ClF5N2
- 4W82FEU838
- LXR-623 (WAY 252623)
- UNII-4W82FEU838
- JMC517161 Compound 12
- orb1307456
- SCHEMBL1407261
- SCHEMBL29377439
- BDBM26066
- LXR623?
- CHEBI:232814
- GLXC-02799
- HMS3748G05
- EX-A1002
- s8390
- AKOS026750209
- CCG-268917
- CS-1721
- EBC-501088
- NCGC00378927-02
- AC-32643
- AC-32644
- AS-74262
- DA-33427
- HY-10629
- LXR-623; WAY-252623
- SY253364
- L0344
Look up LXR-623 in the interactive SynDRA portal →